News | February 08, 2022
GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Ascent Meditech has set benchmarks in introducing pain management products in India. The company has embarked on a new marketing campaign as it plans to enter new markets. Rajiv Mistry, Founder & Managing Director, Ascent Group shares his perspective with Thomas C Thottathil on the road ahead for the company and industry
Vakrangee through its Nextgen Kendras and BharatEasy Mobile Superaap will now be able to provide medicines & healthcare services in remote areas of the country
In March it launched its first plastic-free toothbrush packaging, which included Sensodyne Pronamel and parodontax brushes in the US. Asia Pacific rollout of this commenced in Australia
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Lupin will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations
PEL will explore the PLI scheme and apply if its beneficial.
ranules now has a total of 38 ANDA approvals from US FDA.
Subscribe To Our Newsletter & Stay Updated
